Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.625 AUD | +1.63% | +12.61% | -12.59% |
05-10 | Transcript : 4DMedical Limited - Special Call | |
05-09 | 4DMedical's CT-Based Ventilation Product Secures US Medical Reimbursement for Scans; Shares Rise 5% | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.59% | 161M | - | ||
+12.85% | 229B | B | ||
+13.88% | 195B | B- | ||
+18.39% | 142B | B- | ||
+28.78% | 109B | A- | ||
+2.17% | 64.85B | A- | ||
+18.24% | 54.33B | B+ | ||
+7.04% | 52.09B | B+ | ||
+10.83% | 45.15B | A | ||
+5.94% | 37.39B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4DX Stock
- Ratings 4DMedical Limited